Immunotherapy
Bile acids hinder liver cancer immunotherapy, supplement may help
Scientists at the Salk Institute have found that certain bile acids in the liver suppress immune cells, reducing the effectiveness of immunotherapy for liver cancer. Supplementing with ursodeoxycholic acid (UDCA) reversed this effect in mice, shrinking tumors. UDCA, already approved for other liver conditions, could soon enter clinical trials for cancer treatment.
mRNA covid vaccines may boost cancer immunotherapy survival
An analysis of nearly 1,000 cancer patients shows that mRNA covid-19 vaccines, given soon after starting immune checkpoint inhibitors, nearly doubled survival times for advanced lung and skin cancers. The findings, presented at a medical congress in Berlin, suggest an unexpected immune boost from the vaccines. A clinical trial to confirm these results is set to begin before year's end.
COVID-19 mRNA vaccines linked to longer survival in some lung and skin cancer patients on immunotherapy
Heather Vogel तथ्य-जाँच किया गया
A large retrospective study from the University of Florida and The University of Texas MD Anderson Cancer Center, published in Nature, reports that patients with advanced non-small cell lung cancer or metastatic melanoma lived significantly longer if they received a Pfizer-BioNTech or Moderna COVID-19 mRNA shot within 100 days of starting immune checkpoint inhibitors. The authors stress the findings are observational and will require confirmation in randomized trials.
UMass Amherst nanoparticle vaccine prevents cancers in mice
AI द्वारा रिपोर्ट किया गया
Researchers at the University of Massachusetts Amherst have developed a nanoparticle-based cancer vaccine that prevented melanoma, pancreatic, and triple-negative breast cancers in mice. Up to 88% of vaccinated mice remained tumor-free, with the vaccine also stopping metastasis. The approach uses a 'super adjuvant' to trigger strong immune responses.
Immune drug reduces risk of Merkel cell carcinoma spread
A large clinical trial has shown that the immunotherapy drug pembrolizumab may help prevent the deadly spread of Merkel cell carcinoma, a rare and aggressive skin cancer, after surgery. While it did not significantly reduce overall recurrence rates, the treatment lowered the risk of distant metastases by 42%. The findings offer hope for patients facing this fast-developing disease.